Palonosetron + netupitant

Trade Name:

Akynzeo

Manufacturer/Distributor:

Purdue Pharma

Classification:

Antiemetic

ATC Class:

A04AA55 - palonosetron, combinations

Status:

active

Notice of Compliance (yyyy/mm/dd):

2017/09/28

Date Marketed in Canada (yyyy/mm/dd):

2017/12/04

Presentation:

Capsule: 0.5 mg palonosetron + 300 mg netupitant

Comments:

In combination with dexamethasone, is indicated for once-per-cycle treatment in adult patients for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy OR prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone. Netuptitant is a selective antagonist of human substance P/neurokinin 1 (NK1) receptors. Delayed emesis has been associated with activation of NK1 receptors by substance P. Palonosetron is a 5-HT3 receptor antagonist.

Keywords:

palonosetron

Keywords:

netupitant

Keywords:

vomiting

Keywords:

nausea

Keywords:

drug therapy

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Moroctocog alfa	Xyntha	Hemostatic agent	2009/01/23
Naloxegol	Movantik	Miscellaneous GI drug	2015/08/27
Naltrexone + bupropion	Contrave	Anorexigenic agents	2018/02/13
Naproxen + Esomeprazole	Vimovo	NSAID + PPI	2011/01/14
Nebivolol	Bystolic	Beta-blocker, cardioselective	2013/04
Niraparib	Zejula	Antineoplastic agent	2020/01/09
Norethindrone acetate + ethinyl estradiol	femHRT	estrogen-progesterone combination	2012/10/09
Norgestrel + ethinyl estradiol	Ovral	Oral contraceptive
Ofatumumab	Arzerra	Antineoplastic agent	2012/03/09
Ofatumumab	Kesimpta	Immunomudulator	2021/04/08
Olmesartan	Olmetec	Antihypertensive agent	2009/02
Olmesartan + hydrochlorothiazide	Olmetec Plus	Antihypertensive agent	2009/02
Olopatadine	Pataday	Anti-allergy agent	2011/04/14
Onasemnogene	Zolgensma	Cellular and gene therapy	2021/02/04
Ondansetron	Ondissolve ODF	Antiemetic	2013/04
Oxybutynin	Gelnique	Anticholinergic / Antispasmodic	2012/03/05
Oxybutynin	Uromax	Urinary Antispasmodic
Oxycodone	OxyContin	Narcotic	2012/02/29
Oxycodone	OxyNEO	Narcotic	2012/01/01
Oxycodone + naloxone	Targin	opioid	2009/12/30
Paliperidone	Invega	Antipsychotic agent	2007/10/02
Paliperidone palmitate	Invega Sustenna	Antipsychotic agent	2010/07/28
Palonosetron	Aloxi	5TH3 antagonist	2012/03/14
Palonosetron + netupitant	Akynzeo	Antiemetic	2017/12/04
Pancrelipase	Cotazym ECS 4 & Cotazym 65B	Pancreatic enzymes	2012/02/06
Pasireotide	Signifor	Synthetic analogue of somatostatin	2013/11/26
Patiromer	Veltassa	Potassium binder	2020/03/09
Pazopanib	Votrient	Antineoplastic agent	2011/08/25
Perampanel	Fycompa	Anticonvulsant	2013/09/04
Pertuzumab	Perjeta	Antineoplastic agent	2013/04/23
Phosphate Effervescent	Phosphate Sandoz		2017/01/01
Pirfenidone	Esbriet	Anti-fibrotic agent	2013/01
Plerixafor	Mozobil	Hematopoietic agent	2012/01/26
Pneumococcal 13-valent conjugate vaccine	Prevnar 13	Vaccine	2010/03/17
Polidocanol	Varithena	Sclerosing agent	2015/08/04
Polyethylene glycol 3350	Lax-a-day	Laxative	2009/03/09